We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,238,586 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.73 | 67.66B |
From Apr 2019 to Apr 2024
By Betsy McKay
The National Institutes of Health said Thursday it will begin testing an experimental Ebola vaccine in humans next week, accelerating research as an epidemic caused by the deadly virus continues to ravage West Africa.
GlaxoSmithKline, co-developer of the vaccine candidate along with the National Institute of Allergy and Infectious Diseases, said it will manufacture up to 10,000 doses so that if initial human trials are successful, it can make the stockpile available for further testing or for an emergency immunization program for people at high risk of the disease. More than 1,500 people, or 52% of those infected in the current outbreak, have died.
Scientists will begin enrolling patients early next week in a trial in Bethesda, Md., where the NIH campus is located. The Phase I trial will determine whether the vaccine is safe and generates a protective response in the immmune systems of 20 healthy adult volunteers between the ages of 18 and 50 years.
Write to Betsy McKay at betsy.mckay@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
